2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Glycosidase
  5. Glucosidase Isoform
  6. Glucosidase Inhibitor

Glucosidase Inhibitor

Glucosidase Inhibitors (19):

Cat. No. Product Name Effect Purity
  • HY-113159
    Docosapentaenoic acid (22n-3)
    		Inhibitor 99.87%
    Docosapentaenoic acid (22n-3) is a component of phospholipids. Docosapentaenoic acid 22n-3 has inhibitory activity against α-amylase and α-glucosidase, with IC50s value of 17 μg/mL and 22 μg/mL, respectively. Docosapentaenoic acid 22n-3 increases cell vitality. Docosapentaenoic acid 22n-3 has a weak anti-inflammatory effect.
  • HY-N3405
    Lariciresinol
    		Inhibitor 99.79%
    Lariciresinol is an orally active ingredient. Lariciresinol can be isolated from Arabidopsis thaliana. Lariciresinol inhibits α-glucosidase activity (IC50 of 6.97 μM; Ki of 0.046 μM). Lariciresinol dereases Bcl-2, upregulates Bax and induces Apoptosis. Lariciresinol regulates TGF-β and NF-κB pathways. Lariciresinol has antitumor activity against liver cancer, gastric cancer, and breast cancer. Lariciresinol shows antifungal activity and anti-diabetic activity.
  • HY-N2168
    Pinoresinol 4-O-β-D-glucopyranoside
    		Inhibitor 99.89%
    Pinoresinol 4-O-β-D-glucopyranoside ((+)-Pinoresinol 4-O-β-D-glucopyranoside) is an orally active α-glucosidase inhibitor, with an IC50 of 48.13 μg/mL. Pinoresinol 4-O-β-D-glucopyranoside binds to estrogen receptors. Pinoresinol 4-O-β-D-glucopyranoside inhibits phosphodiesterase. Pinoresinol 4-O-β-D-glucopyranoside exhibits various activities such as antioxidant, anti-inflammatory, anti-hyperglycemic, hepatoprotective and anti-epileptic effects.
  • HY-170588
    α-Glucosidase-IN-78
    		Inhibitor
    α-Glucosidase-IN-78 (Compound 12m) is an inhibitor for α-glucosidase with a reversible, competitive IC50 6.0 μM. α-Glucosidase-IN-78 can be used in research of diabete for its hypoglycemic property.
  • HY-175170
    α-Glucosidase-IN-95
    		Inhibitor
    α-Glucosidase-IN-95 (Compound 21c) is a competitive α-Glucosidase inhibitor with an IC50 of 0.44  μM. α-Glucosidase-IN-95 has a significant inhibitory potency without cytotoxicity to normal cells. α-Glucosidase-IN-95 can be used for metabolic disorders like diabetes mellitus research.
  • HY-168944
    ABCB1-IN-4
    		Inhibitor
    ABCB1-IN-4 (Compound C6z) is an orally active and potent dual α-amylase and α-glucosidase inhibitor with IC50 values of 1.63 μM and 0.14 μM, respectively. ABCB1-IN-4 is promising for research of diabetes.
  • HY-174319
    α-Amylase/α-Glucosidase-IN-20
    		Inhibitor
    α-Amylase/α-Glucosidase-IN-20 (Compound 6b) is a dual inhibitor of α-Amylase and α-Glucosidase with IC50s of 414.57 and 924.15 μM for α-Amylase and α-Glucosidase, respectively. α-Amylase/α-Glucosidase-IN-20 shows a potent anti-diabetic activity, promising for diabetes research.
  • HY-168462
    α-Glucosidase-IN-82
    		Inhibitor
    α-Glucosidase-IN-82 (compound 8l) is a potent inhibitor of α-Glucosidase, with the IC50 of 13.66 μM. α-Glucosidase-IN-82 exhibits a 52-fold increase in inhibitory activity relative to Acarbose (HY-B0089).
  • HY-134960
    2,3-Indolobetulonic acid
    		Inhibitor
    2,3-Indolobetulonic acid (compound 2), a triterpenoid, is α-glucosidase inhibitor with an IC50 of 1.8 µM.
  • HY-N15280
    Terrestrimine
    		Inhibitor
    Terrestrimine is a potent inhibitor of α-Glycosidase, with the IC50 of 225.83 μM. Terrestrimine plays an important role in metabolic disease research.
  • HY-168465
    α-Glucosidase-IN-83
    		Inhibitor
    α-Glucosidase-IN-83 (compound I-1) is a potent inhibitor of α-Glucosidase, with the IC50 of 1.49 μg/mL. α-Glucosidase-IN-83 shows reduction in blood glucose levels in vivo.
  • HY-147964
    α-Glucosidase-IN-9
    		Inhibitor
    α-Glucosidase-IN-9 (compound 7) is a potent α-glucosidase inhibitor, with an IC50 of 55.6 μM. α-Glucosidase-IN-9 can be used for type II diabetes research.
  • HY-176221
    α-Glucosidase-IN-92
    		Inhibitor
    α-Glucosidase-IN-92 (compound 14b) is a non-competitive inhibitor targeting α-glucosidase (IC50=64.0 μM), with better inhibitory potency than Acarbose (HY-B0089) (IC50=750 μM). α-Glucosidase-IN-92 has good oral bioavailability and can cross the blood-brain barrier. α-Glucosidase-IN-92 can delay carbohydrate hydrolysis and reduce postprandial blood glucose. α-Glucosidase-IN-92 can be used in anti-glycemic research for type 2 diabetes.
  • HY-174839
    α-Glucosidase-IN-93
    		Inhibitor
    α-Glucosidase-IN-93 (Compound 5b) is a potent α-glucosidase inhibitor with an IC50 value of 49.18 nM. α-Glucosidase-IN-93 is promising for research of type 2 diabetes.
  • HY-173411
    DNJ-20
    		Inhibitor
    DNJ-20 is an α-glucosidase inhibitor (IC50: 55.3 μg/mL). DNJ-20 has broad-spectrum anti-SARS-CoV-2 activity. DNJ-20 inhibits the correct processing of viral glycoproteins by interfering with the endoplasmic reticulum-associated glycoprotein folding process (ERQC), thereby blocking the formation and infection of viral particles. DNJ-20 has IC50 values up to 1.49 uM against several SARS-CoV-2 variants, as well as HCoV-229E and HCoV-0C43。DNJ-20 can be used for pan-coronavirus research.
  • HY-173035
    α-Glucosidase-IN-85
    		Inhibitor
    α-Glucosidase-IN-85 (Compound 8D1) is the inhibitor for α-Glucosidase with an IC50 of 5.43 μM. α-Glucosidase-IN-85 can be used in research of type 2 diabetes.
  • HY-174840
    α-Glucosidase-IN-94
    		Inhibitor
    α-Glucosidase-IN-94 (Compound 6e) is a potent α-glucosidase inhibitor with an IC50 value of 0.1412 mM. α-Glucosidase-IN-94 is promising for research of type 2 diabetes.
  • HY-113159A
    Docosapentaenoic acid (22n-3) sodium
    		Inhibitor
    Docosapentaenoic acid (22n-3) sodium is a component of phospholipids. Docosapentaenoic acid 22n-3 sodium has inhibitory activity against α-amylase and α-glucosidase, with IC50s value of 17 μg/mL and 22 μg/mL, respectively. Docosapentaenoic acid 22n-3 sodium increases cell vitality. Docosapentaenoic acid 22n-3 sodium has a weak anti-inflammatory effect.
  • HY-N4069
    Lupinalbin A
    		Inhibitor
    Lupinalbin A (Boeravinone L) is a dipeptidyl peptidase 4 (DPP4) and α-glucosidase inhibitor with IC50 values ​​of 45.2 and 53.4 µM, respectively. Lupinalbin A exhibits antidiabetic activity.